Fasoracetam

Fasoracetam

SCHEMBL21178002

NC(N)=O.O=C1CC[C@H](C(=O)N2CCCCC2)N1

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 6/20 0.43
TPSAB1 Q15661 1/20 0.43
TPSD1 Q9BZJ3 1/20 0.43
TPSG1 Q9NRR2 1/20 0.43
HPGD P15428 1/20 0.43
TGM2 P21980 1/20 0.41
CNR2 P34972 1/20 0.40
PARP1 P09874 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
WNT3 P56703 1/20 0.39
SFRP1 Q8N474 1/20 0.39
TRHR P34981 1/20 0.38
POLB P06746 1/20 0.37
HDAC2 Q92769 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fasoracetam SCHEMBL194770 0.95 HPGD (0.47) NAMPTTPSAB1TPSD1TPSG1HPGD
SCHEMBL9735864 0.95 HPGD (0.47) NAMPTTPSAB1TPSD1TPSG1HPGD
Fasoracetam SCHEMBL194771 0.95 HPGD (0.47) NAMPTTPSAB1TPSD1TPSG1HPGD
Fasoracetam SCHEMBL9734362 0.95 HPGD (0.47) NAMPTTPSAB1TPSD1TPSG1HPGD
Fasoracetam SCHEMBL23922653 0.95 HPGD (0.47) NAMPTTPSAB1TPSD1TPSG1HPGD
Fasoracetam SCHEMBL18323021 0.93 HPGD (0.46) NAMPTTPSAB1TPSD1TPSG1HPGD
SCHEMBL9734368 0.93 NAMPT (0.46) NAMPTTPSAB1TPSD1TPSG1HPGD
SCHEMBL5971671 0.93 NAMPT (0.46) NAMPTTPSAB1TPSD1TPSG1HPGD
SCHEMBL9736271 0.93 NAMPT (0.46) NAMPTTPSAB1TPSD1TPSG1HPGD
SCHEMBL7955572 0.88 NAMPT (0.48) NAMPTTPSAB1TPSD1TPSG1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112040938-B Solid forms of fasoracetam 费城儿童医院 2024-06-25 CN disclosed
US-20230203001-A1 SOLID FORMS OF FASORACETAM THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) 2023-06-29 US disclosed
US-11608324-B2 Solid forms of fasoracetam THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) 2023-03-21 US disclosed
US-20210355102-A1 Solid Forms of Fasoracetam THE CHILDREN'S HOSPITAL OF PHILADELPHIA 2021-11-18 US disclosed
CN-112040938-A Solid forms of fasoracetam 费城儿童医院 2020-12-04 CN disclosed
EP-3740204-A1 SOLID FORMS OF FASORACETAM The Children's Hospital Of Philadelphia (US) 2020-11-25 EP disclosed
WO-2019143824-A1 SOLID FORMS OF FASORACETAM AEVI GENOMIC MEDICINE, INC. (US) 2019-07-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210355102-A1 Solid Forms of Fasoracetam FAH, FASN, PFAS NAMPT 1232/4885TPSAB1 3956/4885TPSD1 4537/4885
US-20230203001-A1 SOLID FORMS OF FASORACETAM FAH, FASN, PFAS NAMPT 1232/4885TPSAB1 3956/4885TPSD1 4537/4885
US-11608324-B2 Solid forms of fasoracetam FAH, FASN, PFAS NAMPT 1232/4885TPSAB1 3956/4885TPSD1 4537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.